Alternate SlyA and H-NS nucleoprotein complexes control hlyE expression in Escherichia coli K-12.

Mol Microbiol

Department of Molecular Biology and Biotechnology, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK.

Published: November 2007

Haemolysin E is a cytolytic pore-forming toxin found in several Escherichia coli and Salmonella enterica strains. Expression of hlyE is repressed by the global regulator H-NS (histone-like nucleoid structuring protein), but can be activated by the regulator SlyA. Expression of a chromosomal hlyE-lacZ fusion in an E. coli slyA mutant was reduced to 60% of the wild-type level confirming a positive role for SlyA. DNase I footprint analysis revealed the presence of two separate SlyA binding sites, one located upstream, the other downstream of the hlyE transcriptional start site. These sites overlap AT-rich H-NS binding sites. Footprint and gel shift data showed that whereas H-NS prevented binding of RNA polymerase (RNAP) at the hlyE promoter (PhlyE), SlyA allowed binding of RNAP, but inhibited binding of H-NS. Accordingly, in vitro transcription analyses showed that addition of SlyA protein relieved H-NS-mediated repression of hlyE. Based on these observations a model for SlyA/H-NS regulation of hlyE expression is proposed in which the relative concentrations of SlyA and H-NS govern the nature of the nucleoprotein complexes formed at PhlyE. When H-NS is dominant RNAP binding is inhibited and hlyE expression is silenced; when SlyA is dominant H-NS binding is inhibited allowing RNAP access to the promoter facilitating hlyE transcription.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2156107PMC
http://dx.doi.org/10.1111/j.1365-2958.2007.05950.xDOI Listing

Publication Analysis

Top Keywords

hlye expression
12
h-ns
8
slya h-ns
8
nucleoprotein complexes
8
hlye
8
escherichia coli
8
slya
8
binding sites
8
h-ns binding
8
binding inhibited
8

Similar Publications

Bacterial Living Therapeutics with Engineered Protein Secretion Circuits to Eliminate Breast Cancer Cells.

ACS Synth Biol

October 2024

UNAM─Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara 06800, Turkey.

Cancer therapy can be limited by potential side effects, and bacteria-based living cancer therapeutics have gained scientific interest in recent years. However, the full potential of bacteria as therapeutics has yet to be explored due to engineering challenges. In this study, we present a bacterial device designed to specifically target and eliminate breast cancer cells.

View Article and Find Full Text PDF

Sialidase-Chimeric Bioengineered Bacteria for Tumor-Sialoglycan-Triggered Solid Tumor Therapy.

Nano Lett

August 2024

Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, P. R. China.

Adoptive cell therapies for solid tumors are usually limited by off-target antigens, incapable tissue infiltration, and cell function exhaustion. In contrast, bacterial cells possess the inherent competencies of preferential tumor targeting, deep tissue penetration, and high intratumoral bioactivity and represent promising alternatives to overcome these challenges. Here, a sialic-acid-responsive regulatory gene circuit is engineered into MG1655 to express cytolysin of hemolysin E (HlyE).

View Article and Find Full Text PDF

Dual role of CsrA in regulating the hemolytic activity of O157:H7.

Virulence

December 2022

Laboratory of Bacterial Pathogenesis, Department of Microbiology and Immunology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Post-transcriptional global carbon storage regulator A (CsrA) is a sequence-specific RNA-binding protein involved in the regulation of multiple bacterial processes. Hemolysin is an important virulence factor in the enterohemorrhagic O157:H7 (EHEC). Here, we show that CsrA plays a dual role in the regulation of hemolysis in EHEC.

View Article and Find Full Text PDF

Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors.

Sci Rep

March 2021

Department of Medical Laboratory Science and Biotechnology, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan.

Bacterial cancer therapy was developed using probiotic Escherichia coli Nissle 1917 (EcN) for medical intervention of colorectal cancer. EcN was armed with HlyE, a small cytotoxic protein, under the control of the araBAD promoter (P). The intrinsic limitation of P for the gene expression is known to be negated by glucose and afflicted with all-or-nothing induction in host bacteria.

View Article and Find Full Text PDF

The SlyA transcriptional regulator controls the expression of genes involved in virulence and production of surface components in and . Its mode of action is mainly explained by its antagonism with the H-NS repressor for the same DNA binding regions. Interestingly, it has been reported that the alarmone ppGpp promotes SlyA dimerization and DNA binding at the promoter of , enhancing the expression of this gene in .

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!